• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Processing of chromogranins/secretogranin in patients with diabetic retinopathy.

作者信息

Fournier Isabelle, Gaucher David, Chich Jean-F, Bach Charlotte, Shooshtarizadeh Peiman, Picaud Serge, Bourcier Tristan, Speeg-Schatz Claude, Strub Jean M, Van Dorsselaer Alain, Corti Angelo, Aunis Dominique, Metz-Boutigue Marie-H

机构信息

Department of Ophthalmology, University Hospital of Strasbourg, Strasbourg, France; Physiopathology of Nervous System, University of Strasbourg, INSERM Z575, Strasbourg, France.

出版信息

Regul Pept. 2011 Feb 25;167(1):118-24. doi: 10.1016/j.regpep.2010.12.004. Epub 2010 Dec 24.

DOI:10.1016/j.regpep.2010.12.004
PMID:21185877
Abstract

AIMS

Inflammation has been linked to the development of diabetic retinopathy (DR). Chromogranins A, B (CgA, CgB) and secretogranin II (SgII), are prohormones overexpressed in inflammatory diseases. The present study was conducted to evaluate the presence and processing of these prohormones in the vitreous of patients with DR (DV), compared with nondiabetic vitreous (NDV).

METHODS

Thirteen DV and 14 NDV samples were collected during vitreoretinal surgery. ELISA, Western blot, RP-HPLC, dot blot, protein sequencing and mass spectrometry were used to study the quantitative expression and the processing of CgA, CgB and SgII.

RESULTS

CgA, CgB and SgII presence was higher in DV than in NDV. Mean concentration of CgA evaluated by ELISA was 90.8 (± 90.1) n L⁻¹ in DV vs. 29.7 (±20.9) in NDV (p=0.039). In NDV, Western blot indicated that only short CgB-derived peptides were identified. In DV, proteomic analyses showed that long CgA-, CgB- and SgII-derived fragments and α1-antitrypsin were overexpressed, suggesting possible inhibition of the proteolytic process.

CONCLUSIONS

This study shows differences in the presence and endogenous processing of CgA, CgB and SgII from DV vs. NDV. In DV, the increase of complete granins and the attenuation of their endogenous proteolytic processing could participate in DR progression by reducing the presence of regulatory peptides, important for the pro-/anti-angiogenic balance in the eye.

摘要

相似文献

1
Processing of chromogranins/secretogranin in patients with diabetic retinopathy.
Regul Pept. 2011 Feb 25;167(1):118-24. doi: 10.1016/j.regpep.2010.12.004. Epub 2010 Dec 24.
2
Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II.人神经内分泌肿瘤中的分泌粒蛋白III:与嗜铬粒蛋白A、B及分泌粒蛋白II的比较性免疫组织化学研究
Regul Pept. 2010 Nov 30;165(1):30-5. doi: 10.1016/j.regpep.2010.06.002. Epub 2010 Jun 12.
3
Aspects of the neuroendocrine cerebellum: expression of secretogranin II, chromogranin A and chromogranin B in mouse cerebellar unipolar brush cells.神经内分泌小脑的相关方面:分泌粒蛋白II、嗜铬粒蛋白A和嗜铬粒蛋白B在小鼠小脑单极刷状细胞中的表达
Neuroscience. 2009 Sep 1;162(3):673-87. doi: 10.1016/j.neuroscience.2009.02.017. Epub 2009 Feb 13.
4
Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system.嗜铬粒蛋白A和B以及分泌粒蛋白II作为来自弥散神经内分泌系统的调节肽的激素原。
Results Probl Cell Differ. 2010;50:21-44. doi: 10.1007/400_2009_26.
5
Chromogranins A and B and secretogranin II: evolutionary and functional aspects.嗜铬粒蛋白A、B和分泌粒蛋白II:进化与功能方面
Acta Physiol (Oxf). 2008 Feb;192(2):309-24. doi: 10.1111/j.1748-1716.2007.01806.x. Epub 2007 Nov 15.
6
Chromogranin A, chromogranin B and secretogranin II mRNAs in the pituitary and adrenal glands of various mammals. Regulation of chromogranin A, chromogranin B and secretogranin II mRNA levels by estrogen.多种哺乳动物垂体和肾上腺中的嗜铬粒蛋白A、嗜铬粒蛋白B和分泌粒蛋白II信使核糖核酸。雌激素对嗜铬粒蛋白A、嗜铬粒蛋白B和分泌粒蛋白II信使核糖核酸水平的调节。
Lab Invest. 1992 Sep;67(3):394-404.
7
Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.源自嗜铬粒蛋白的肽作为内分泌肿瘤的诊断和预后标志物。
Regul Pept. 2010 Nov 30;165(1):5-11. doi: 10.1016/j.regpep.2009.11.013. Epub 2009 Nov 26.
8
Presence of secretogranin II and high-capacity, low-affinity Ca2+ storage role in nucleoplasmic Ca2+ store vesicles.分泌粒蛋白II的存在以及在核质钙储存囊泡中的高容量、低亲和力钙储存作用。
Biochemistry. 2007 Dec 18;46(50):14663-71. doi: 10.1021/bi701339m. Epub 2007 Nov 20.
9
Regulatory peptides from chromogranin A and secretogranin II.来自嗜铬粒蛋白 A 和分泌颗粒蛋白 II 的调节肽。
Cell Mol Neurobiol. 2010 Nov;30(8):1145-6. doi: 10.1007/s10571-010-9552-6. Epub 2010 Nov 19.
10
Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions.来自嗜铬粒蛋白A和分泌粒蛋白II的调节肽:炎症相关细胞和组织的潜在调节因子。
Regul Pept. 2010 Nov 30;165(1):45-51. doi: 10.1016/j.regpep.2009.09.009. Epub 2009 Oct 1.

引用本文的文献

1
Role and function of granin proteins in diabetes mellitus.嗜铬粒蛋白在糖尿病中的作用与功能。
World J Diabetes. 2021 Jul 15;12(7):1081-1092. doi: 10.4239/wjd.v12.i7.1081.
2
The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.嗜铬粒蛋白及其衍生多肽在动脉粥样硬化、糖尿病和冠心病中的新作用
Int J Mol Sci. 2021 Jun 6;22(11):6118. doi: 10.3390/ijms22116118.
3
Chromogranins: from discovery to current times.嗜铬粒蛋白:从发现到现在。
Pflugers Arch. 2018 Jan;470(1):143-154. doi: 10.1007/s00424-017-2027-6. Epub 2017 Sep 5.
4
Chromogranin A: a paradoxical player in angiogenesis and vascular biology.嗜铬粒蛋白A:血管生成与血管生物学中一个矛盾的参与者。
Cell Mol Life Sci. 2015 Jan;72(2):339-48. doi: 10.1007/s00018-014-1750-9. Epub 2014 Oct 9.
5
Mapping the extracellular and membrane proteome associated with the vasculature and the stroma in the embryo.绘制胚胎血管和基质相关的细胞外和膜蛋白组图谱。
Mol Cell Proteomics. 2013 Aug;12(8):2293-312. doi: 10.1074/mcp.M112.024075. Epub 2013 May 14.
6
The extended granin family: structure, function, and biomedical implications.延伸的颗粒家族:结构、功能和生物医学意义。
Endocr Rev. 2011 Dec;32(6):755-97. doi: 10.1210/er.2010-0027. Epub 2011 Aug 23.